Compare VanEck Gold Miners ETF (GDX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Sana Biotechnology Inc — how do they compare? VanEck Gold Miners ETF trades at $89.31 (market cap $25.65B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: VanEck Gold Miners ETF is far larger — about 30.7× Sana Biotechnology Inc's market cap, and VanEck Gold Miners ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Sana Biotechnology Inc for 23 Days on average.
| GDX | SANA | |
|---|---|---|
Market Cap | $25.65B | $836.71M |
Volume | 16,534,046 | 4,507,444 |
52-Week High | $115.84 | $5.92 |
52-Week Low | $68.28 | $2.68 |
Typical Hold Time | 76 Days | 23 Days |
Sector | — | Health |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $89.24, up 4.42% today but facing bearish technical signals with 15 sell indicators versus 4 buy signals. The ETF remains 22% below its peak despite gold trading near $4,270, creating a potential catch-up opportunity. Recent institutional activity shows mixed sentiment with Allworth Financial and HB Wealth Management reducing positions while Ameritas Advisory Services increased its stake by 315.7%.
Gold miners offer leverage to gold prices but face volatility from interest rate sensitivity and operational risks. Current technical weakness suggests near-term pressure, though long-term fundamentals remain supported by gold's defensive characteristics amid macroeconomic uncertainty. The divergence between physical gold performance and miner valuations presents both risk and opportunity for investors.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
